Technology investors are increasing their bullish bet on Intel (INTC). Team “Blue” hired a new CEO, Lip-Bu Tan. Although he shared Gelsinger’s vision on computer chip development, they have differences in leadership.
CEO Tan will pivot Intel into the AI server market craze. Furthermore, he will continue to aggressively cut the middle management later. Before ex-CEO Gelsinger’s exit, Intel cut over 15% of its staff, or 15,000 jobs. Intel is in a better position to post profits after lowering its operating costs. Cutting management will enable the firm to make faster decisions.
Enphase (ENPH) gained 9.75% on Monday to close at $63.80. Only now are markets reacting to the firm posting strong Q4 net profits of $62.2 million, or $0.45 per share on Feb. 5, 2025. The company expects its new products to drive revenue growth this year. In the second half of the year, growth will reaccelerate.
Incyte (INCY) continued to sell off on Monday. Shares lost 8.62% yesterday in response to its late-stage trial results for povorcitinib. This is a drug that treats an inflammatory skin condition called hidradenitis suppurativa. The drugs met their primary endpoint.
Investors may take advantage of INCY stock dipping to start a small position.
